AA4500
Sponsors
Endo Pharmaceuticals, Gerut, Zachary, M.D.
Conditions
Advanced Dupuytren's DiseaseLipomaPeyronie's Disease
Phase 2
The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease
CompletedNCT00755222
Start: 2008-08-31End: 2009-12-31Updated: 2017-10-05
Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease
CompletedNCT01430169
Start: 2011-09-30End: 2011-11-30Updated: 2017-10-05
Double Blind Study to Evaluate the Efficacy of Collagenase Histolyticum in the Treatment of Lipoma
CompletedNCT02249052
Start: 2014-08-31End: 2016-06-30Updated: 2017-02-23
Phase 3
AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease
CompletedNCT00528424
Start: 2007-12-31End: 2008-11-30Updated: 2017-12-02
Study of AA4500 in the Treatment of Peyronie's Disease
CompletedNCT01221623
Start: 2010-10-31End: 2012-03-31Updated: 2017-10-05
Study of AA4500 in the Treatment of Peyronie's Disease
CompletedNCT01221597
Start: 2010-09-30End: 2012-04-30Updated: 2017-10-05
A Study of AA4500 in Men With Peyronie's Disease
CompletedNCT01243411
Start: 2010-11-30End: 2012-08-31Updated: 2017-10-05
A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease
CompletedNCT01685437
Start: 2012-09-30End: 2013-12-31Updated: 2017-10-05
An Open-label Study to Assess the Safety and Effectiveness of AA4500 in Combination With the ErecAid® Esteem® Manual Vacuum Therapy System in Treating Men With Peyronie's Disease
CompletedNCT02267460
Start: 2014-10-31End: 2016-03-31Updated: 2017-11-08